AIPRI and ACCOMPLISH studies. Whether we have effective methods of „cardionephroprotection”? Review article
Article Sidebar
Published:
Jun 30, 2011
Keywords:
arterial hypertension, subclinical organ damages, benazepril
Main Article Content
Abstract
The inhibition of the renin-angiotensin-aldosterone (ACE) system plays an important role in the antihypertensive therapy designed to prevent target organ damages and to improve patients’ prognosis. The AIPRI Study results confirmed that pharmalogical treatment with ACE inhibitor – benazepril in this group of patients allows significantly reduce the risk of end-stage renal disease and the need of renal replacement therapy. Also the ACCOMPLISH trial demonstrated that use of benazepril in combination therapy of hypertension is associated with significant cardiovascular and renal risk reduction.
Article Details
How to Cite
Grabysa , R. (2011). AIPRI and ACCOMPLISH studies. Whether we have effective methods of „cardionephroprotection”?. Medycyna Faktow (J EBM), 4(2(11), 59-65. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2536
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Mathers C., Stevens G., Mascarenas M.: Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization, 2009 [online].
2. MacMahon S., Peto R., Butler J. et al.: Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
3. Kannel W.B.: Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275(20): 1571-1576.
4. Klag M.J., Whelton P.K., Randall B.L. et al.: Blood pressure and end-stage renal disease in men. N. Engl. J. Med. 1996; 334: 13-18.
5. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Hypertension (ESH). J. Hypertens. 2007; 25: 1105-87.
6. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009; 27: 2121-58.
7. Stevens L.A., Coresh J., Greene T., Levey A.S.: Assessing kidney function – measured and estimated glomerular filtration rate. N. Engl. J. Med. 2006; 354: 2473-2483.
8. Foley R.N., Parfrey P.S., Sarnak M.J.: Clinical epidemiology of cardiovascular disease in chronic kidney disease. Am. J. Kidney Dis. 1998; 32(suppl 3): S112-S119.
9. Król E., Rukowski B.: Przewlekła choroba nerek – klasyfikacja, epidemiologia i diagnostyka. Forum Nefrologiczne 2008; 1(1): 1-6.
10. Levey A.S., Eckhardt K.U., Tsukamoto Y. et al.: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100.
11. Fox C.S., Larson M.G., Leip E.P. et al.: Predictors of new-onset kidney disease in community-based population. JAMA 2004; 291: 844-50.
12. Wang Y., Chen X., Song Y. et al.: Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008; 73: 19-33.
13. Go A.S., Chertow G.M., Fan D. et al.: Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296-305.
14. Remuzzi G., Perico N., Mancia M. et al.: The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. Suppl. 2005; 99:S57-S65.
15. Brewster U.C., Perazella M.A.: The rennin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am. J. Med. 2004; 116: 263-72.
16. Culleton B.F., Larson M.G., Wilson P.W., Evans J.C., Parfrey P.S., Levy D.: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999; 56: 2214-2219.
17. Kronenberg F., Kuen E., Ritz E. et al.: Lipoprotein (a) serum concentrations and apolipoprotein (a) phenotypes in mild and moderate renal failure. J. Am. Soc. Nephrol. 2000; 11: 105-115.
18. Fliser D., Pacini G., Engelleiter R. et al.: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998; 53: 1343-1347.
19. James M.T., Hammelgarn B.R., Tonelli M.: Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-309.
20. Maschio G., Alberti D., Janin G. et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334: 939-45.
21. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril in decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1957-63.
22. Jamerson K., Weber M.A., Bakris G.L. et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
23. Bakris G.L., Serafidis P.A., Weir M.R. et al.: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. Lancet 2010; 375: 1173-1181.
2. MacMahon S., Peto R., Butler J. et al.: Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
3. Kannel W.B.: Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275(20): 1571-1576.
4. Klag M.J., Whelton P.K., Randall B.L. et al.: Blood pressure and end-stage renal disease in men. N. Engl. J. Med. 1996; 334: 13-18.
5. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Hypertension (ESH). J. Hypertens. 2007; 25: 1105-87.
6. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009; 27: 2121-58.
7. Stevens L.A., Coresh J., Greene T., Levey A.S.: Assessing kidney function – measured and estimated glomerular filtration rate. N. Engl. J. Med. 2006; 354: 2473-2483.
8. Foley R.N., Parfrey P.S., Sarnak M.J.: Clinical epidemiology of cardiovascular disease in chronic kidney disease. Am. J. Kidney Dis. 1998; 32(suppl 3): S112-S119.
9. Król E., Rukowski B.: Przewlekła choroba nerek – klasyfikacja, epidemiologia i diagnostyka. Forum Nefrologiczne 2008; 1(1): 1-6.
10. Levey A.S., Eckhardt K.U., Tsukamoto Y. et al.: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100.
11. Fox C.S., Larson M.G., Leip E.P. et al.: Predictors of new-onset kidney disease in community-based population. JAMA 2004; 291: 844-50.
12. Wang Y., Chen X., Song Y. et al.: Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008; 73: 19-33.
13. Go A.S., Chertow G.M., Fan D. et al.: Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296-305.
14. Remuzzi G., Perico N., Mancia M. et al.: The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. Suppl. 2005; 99:S57-S65.
15. Brewster U.C., Perazella M.A.: The rennin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am. J. Med. 2004; 116: 263-72.
16. Culleton B.F., Larson M.G., Wilson P.W., Evans J.C., Parfrey P.S., Levy D.: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999; 56: 2214-2219.
17. Kronenberg F., Kuen E., Ritz E. et al.: Lipoprotein (a) serum concentrations and apolipoprotein (a) phenotypes in mild and moderate renal failure. J. Am. Soc. Nephrol. 2000; 11: 105-115.
18. Fliser D., Pacini G., Engelleiter R. et al.: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998; 53: 1343-1347.
19. James M.T., Hammelgarn B.R., Tonelli M.: Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-309.
20. Maschio G., Alberti D., Janin G. et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334: 939-45.
21. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril in decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1957-63.
22. Jamerson K., Weber M.A., Bakris G.L. et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
23. Bakris G.L., Serafidis P.A., Weir M.R. et al.: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. Lancet 2010; 375: 1173-1181.